Description
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.